Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia
about
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceClass III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory AnalysisMolecular Genetic Markers in Acute Myeloid LeukemiaCore Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic OpportunitiesGenetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemiaFrom the Biology of PP2A to the PADs for Therapy of Hematologic MalignanciesEssential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancersModeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemiasPrognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.Molecular signatures in acute myeloid leukemia.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Increased expression of miR-24 is associated with acute myeloid leukemia with t(8;21).Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean PopulationHigh-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.Overexpression and knockout of miR-126 both promote leukemogenesisMicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA.inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland.Prognostic markers in AML: focus on CBFLMolecular pathogenesis of core binding factor leukemia: current knowledge and future prospects.New agents for acute myeloid leukemia: is it time for targeted therapies?Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Ras-Erk signaling induces phosphorylation of human TLE1 and downregulates its repressor function.Molecular landscape in acute myeloid leukemia: where do we stand in 2016Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta.RUNX1-ETO Leukemia.
P2860
Q26776393-2A3678C6-9E81-4AD5-9726-5C03C3E41891Q26797245-BAB4CA0C-C0A6-4E17-844E-9A43A6816B61Q26799606-66CD26B2-FD10-4268-AF40-83F720A1BEF1Q26863756-B544DDD7-F2BB-4FD5-B1ED-B0222BF6517DQ33555627-C8C18C2B-08B0-4727-A483-F52C82237343Q33774508-F3CBA82C-7135-4E24-928A-07656637B395Q34043449-DC841A3B-49F2-4A2C-A430-8DC5EDBDA8E7Q34104555-7A4CBAA8-F730-416D-85E8-658BFB44E82CQ34169601-850A2BF5-70C0-4C2A-BEE0-DA8C20F87DBFQ34255090-493F8451-62BA-4090-857C-71D943258F81Q34403639-2E1D1F76-A906-4358-A0AD-B51C0DCC82F2Q34663691-4F563459-1186-4F54-BB44-596336D1EBE1Q34732919-55723958-22EB-471E-B04E-89744F8D9C9FQ35332017-812E4112-5B66-4B37-82BE-96D51CCA121CQ35849281-72069BD6-F689-4EB2-AD31-E6950909CABBQ36193187-D59CC2A3-46B7-4BCE-AD90-70020C11D33DQ36366621-D95BB96C-74C6-456E-BAD2-C1FADECA5486Q36529502-74EABCF7-F4B8-48F7-9446-D51892A5C824Q36582324-863D4513-22B6-42FA-857D-19CB913FF22AQ36852251-96220014-4FFA-4234-942F-E819C16AEE10Q37871413-C462636C-F310-475F-83DB-9277221FC963Q37973135-9413CADF-7942-41F3-89A8-C749056B3AA7Q38263126-49192551-BC35-4CA0-AFEE-68A05F007DA6Q38964113-09DF9200-EF83-4859-936D-9FA99EF4B69DQ39116878-6C285D97-6CF2-486F-9BC8-EF7F2FA6C0B8Q41973082-CDBA3B64-9FCB-4966-BB0D-BABF240306C2Q50893694-15FBF0E0-A5FA-4A15-B209-8B078A316D53Q51039848-E948CEB8-1E30-40D2-8716-80E2FECEE8DAQ51097627-683EA1A4-4D18-4C44-936B-2E4C172B0F66
P2860
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Advances in molecular genetics ...... factor acute myeloid leukemia
@ast
Advances in molecular genetics ...... factor acute myeloid leukemia
@en
Advances in molecular genetics ...... factor acute myeloid leukemia
@nl
type
label
Advances in molecular genetics ...... factor acute myeloid leukemia
@ast
Advances in molecular genetics ...... factor acute myeloid leukemia
@en
Advances in molecular genetics ...... factor acute myeloid leukemia
@nl
prefLabel
Advances in molecular genetics ...... factor acute myeloid leukemia
@ast
Advances in molecular genetics ...... factor acute myeloid leukemia
@en
Advances in molecular genetics ...... factor acute myeloid leukemia
@nl
P2860
P50
P1476
Advances in molecular genetics ...... factor acute myeloid leukemia
@en
P2093
Peter Paschka
P2860
P304
P356
10.1097/CCO.0B013E32831369DF
P577
2008-11-01T00:00:00Z